Abstract
A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. This compound is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.
MeSH terms
-
Administration, Topical
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / chemistry*
-
Boron Compounds / administration & dosage
-
Boron Compounds / chemistry*
-
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
-
Bridged Bicyclo Compounds, Heterocyclic / chemistry*
-
Dermatitis, Atopic / drug therapy*
-
Dermatitis, Atopic / pathology
-
Dermatologic Agents / administration & dosage
-
Dermatologic Agents / chemistry*
-
Edema / drug therapy
-
Edema / pathology
-
Humans
-
Mice
-
Psoriasis / drug therapy*
-
Psoriasis / pathology
-
Structure-Activity Relationship
-
U937 Cells
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Boron Compounds
-
Bridged Bicyclo Compounds, Heterocyclic
-
Dermatologic Agents
-
crisaborole